Ensysce Biosciences up on partnership for pain therapy development

Ensysce Biosciences

31/08/2022 19:37

** Drug developer Ensysce Biosciences Inc's shares  ENSC.O 
up 4% at $42
    ** Company partners with Quotient Sciences to accelerate
development of its experimental opioid combination product,
PF614-MPAR, as a treatment for chronic pain  urn:newsml:reuters.com:*:nPrekKfyxa
    ** Ensysce says PF614-MPAR is designed to reduce the risk of
abuse and overdose
    ** Including session's gains, company's shares down ~91% YTD

 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com))